You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

TESTODERM TTS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Testoderm Tts patents expire, and when can generic versions of Testoderm Tts launch?

Testoderm Tts is a drug marketed by Alza and is included in one NDA.

The generic ingredient in TESTODERM TTS is testosterone. There are sixty-nine drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Testoderm Tts

A generic version of TESTODERM TTS was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.

  Sign Up

US Patents and Regulatory Information for TESTODERM TTS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alza TESTODERM TTS testosterone FILM, EXTENDED RELEASE;TRANSDERMAL 020791-001 Dec 18, 1997 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TESTODERM TTS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alza TESTODERM TTS testosterone FILM, EXTENDED RELEASE;TRANSDERMAL 020791-001 Dec 18, 1997 ⤷  Sign Up ⤷  Sign Up
Alza TESTODERM TTS testosterone FILM, EXTENDED RELEASE;TRANSDERMAL 020791-001 Dec 18, 1997 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for TESTODERM TTS

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Warner Chilcott UK Ltd. Intrinsa testosterone EMEA/H/C/000634
Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
Warner Chilcott  Deutschland GmbH Livensa testosterone EMEA/H/C/000630
Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for TESTODERM TTS

See the table below for patents covering TESTODERM TTS around the world.

Country Patent Number Title Estimated Expiration
Mexico 161285 MEJORAS A VENDAJE O PARCHE PARA COADMINISTRAR UNA DROGA Y UN MEJORADOR DE ABSORCION PERCUTANEA A UN AREA PREDETERMINADA DE PIEL NO ROTA,DURANTE UN TIEMPO PREDETERMINADO ⤷  Sign Up
Ireland 52930 DOSAGE FORM FOR COADMINISTERING DRUG AND PERCUTANEOUS ABSORPTION ENHANCER ⤷  Sign Up
Cyprus 1400 DOSAGE FORM FOR COADMINISTERING DRUG AND PERCUTANEOUS ABSORPTION ENHANCER ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.